Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

Related Articles

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

2 months ago

Is Arcturus Therapeutics Poised for a Massive Upside in 2026

2 months ago

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

6 days ago

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

2 months ago

Category

You may also like

Stock News•3 days ago

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Protagenic Therapeutics (OTCQB:PTIX) engaged Floyd Regulatory Strategic Consulting and Danforth Health to support the clinical development of its lead candidate, PT00114. These partnerships aim to acc...

PTIX

Share

Stock News•1 week ago

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen reported preliminary positive data from the open-label extension of its PALISADE-3 Phase 3 study of fasedienol. The intranasal candidate targets social anxiety disorder via a novel nose-to-br...

VTGN

Share

Stock News•1 week ago

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie Inc. (BIVI) detailed the mechanism of action for its drug candidate, bezisterim, highlighting its potential to address underlying pathology in Parkinson's disease. The discussion focused on the...

BIVI

Share

Stock News•4 weeks ago

BrainsWay: Competitive Threats Are Mounting

BrainsWay continues to report strong growth and margin expansion, driven by recurring revenue and expanded TMS indications like adolescent depression. However, the company faces long-term competitive ...

BWAY

Share